BMY vs ABBV vs NVS Stock Comparison

Bristol Myers Squibb, AbbVie and Novartis Ag Prices as of Nov 13, 2026 Peers: Industry group
BMY Bristol Myers Squibb Co
$63.43 +7.0% 1M +30.4% 1Y
Market cap
$129.31B
P/E
14.0x
Revenue (TTM)
$50.03B
Div. yield
–
Pharmaceuticals Healthcare
5 wins
ABBV AbbVie Inc.
$295.14 +4.1% 1M +27.1% 1Y
Market cap
$523.52B
P/E
50.6x
Revenue (TTM)
$66.01B
Div. yield
–
Pharmaceuticals Healthcare
6 wins
NVS Novartis Ag
$160.55 +9.3% 1M +21.7% 1Y
Market cap
$313.37B
P/E
17.9x
Revenue (TTM)
—
Div. yield
–
Pharmaceuticals Healthcare

Head to Head

11 decided of 12

AbbVie leads on 6 of the 12 questions below (AbbVie 6, Bristol Myers Squibb 5). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionBMYABBVNVSLeader
Larger companyMarket capitalisation $129.31B $523.52B $313.37B ABBV
Cheaper on earningsLower P/E, profitable companies only 14.0x 50.6x 17.9x BMY
Cheaper on forward earningsLower price / next fiscal year consensus EPS 9.4x 22.0x 17.1x BMY
Faster revenue growthRevenue growth, trailing twelve months +4.2% +10.7% — ABBV
More profitableNet margin, trailing twelve months 18.5% 15.7% — BMY
Better return on capitalReturn on invested capital 14.0% 24.3% — ABBV
Less leveragedLower net debt / EBITDA 2.1x 2.4x — BMY
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +30.4% +27.1% +21.7% BMY
Better 5-year returnAnnualised price return, 5 years +1.3%/yr +20.3%/yr +14.3%/yr ABBV
Less volatileAnnualised volatility, 1 year 27.9% 25.3% 27.8% ABBV
Higher overall scoreMean of the five percentile scores vs peers 66/100 70/100 — ABBV

Percentile Scorecard

BMYABBVNVS

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisBMYABBVNVS
Valuation 86 #91 of 660 90 #68 of 660 96 #26 of 660
Growth 48 #323 of 619 67 #204 of 619 –
Profitability 92 #46 of 595 96 #23 of 595 –
Financial Health 21 #542 of 683 15 #580 of 683 –
Shareholder Returns 82 #82 of 459 81 #89 of 459 79 #97 of 459
Overall 66 70 –
  • BMY ranked among 695 companies in Pharmaceuticals and Biotechnology
  • ABBV ranked among 695 companies in Pharmaceuticals and Biotechnology
  • NVS ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodBMYABBVNVSSPY
1 month +7.0%+4.1%+9.3% -2.0%
3 months -0.6%+18.3%+6.4% -2.8%
6 months +11.3%+40.3%+8.4% +2.0%
Year to date +17.6%+29.2%+16.5% +10.6%
1 year +30.4%+27.1%+21.7% +12.2%
3 years +25.6%+113.8%+69.2% +68.1%
3 years, per year +7.9%+28.8%+19.2% +18.9%
5 years +6.7%+152.3%+94.6% +61.4%
5 years, per year +1.3%+20.3%+14.3% +10.1%
10 years +12.5%+367.7%+118.5% +248.5%
10 years, per year +1.2%+16.7%+8.1% +13.3%

Risk

MeasureBMYABBVNVSSPY
Volatility, 1Y 27.9%25.3%27.8% 13.6%
Downside volatility, 1Y 25.9%24.1%30.0% 13.9%
Beta vs S&P 500, 1Y 0.23-0.020.36 1.00
Return / volatility, 1Y 1.091.070.78 0.90
Max drawdown, 5Y -51.1%-24.3%-20.4% -25.4%
From 52-week high -6.8%0.0%-4.8% -3.2%
52-week high $68.09$295.14$168.62 $779.14
52-week low $45.79$197.38$124.36 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleBMYABBVNVS
P/E now vs peer median 14.0xmedian 17.0x 50.5xmedian 17.0x 17.9xmedian 17.0x
P/S now vs peer median 2.6xmedian 8.4x 7.9xmedian 8.4x 5.1xmedian 8.4x
EV/EBITDA now vs peer median 11.3xmedian 14.6x 20.4xmedian 14.6x —median 14.6x
P/FCF now vs peer median 14.0xmedian 19.0x 27.6xmedian 19.0x 14.3xmedian 19.0x
P/B now vs peer median 5.5xmedian 2.0x -113.8xmedian 2.0x —median 2.0x
PEG now vs peer median 3.60median 0.43 3.03median 0.43 —median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsBMYABBVNVS
Revenue $50.03B $66.01B –
Gross profit $34.64B $48.67B –
Operating income $11.33B $21.23B –
Net income $9.24B $10.35B –
Free cash flow $9.29B $18.87B –
R&D $10.56B $9.96B –
EPS (diluted) $4.50 $5.84 –
Cash & equivalents $9.57B $10.77B $400.00M
Total debt $42.88B $80.90B –
Shares (diluted) 2.05B 1.77B 1.96B
Enterprise value $84.50B $491.53B $286.61B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricBMYABBVNVS
P/E 14.0x 50.5x 17.9x
P/FCF 14.0x 27.6x 14.3x
P/Operating cash flow 12.2x 26.0x –
P/S 2.6x 7.9x 5.1x
P/B 5.5x -113.8x –
P/Tangible book 20.0x -8.5x –
EV/EBITDA 11.3x 20.4x –
EV/EBIT 14.1x 27.9x –
EV/Revenue 3.2x 9.0x –
EV/FCF 17.2x 31.4x –
EV/Operating cash flow 15.0x 29.5x –
PEG (3Y EPS CAGR) 3.60 3.03 –

Growth

14 metrics
MetricBMYABBVNVS
Revenue growth (1Y) 4.2% 10.7% –
Revenue CAGR (3Y) 3.6% 6.2% –
Gross profit growth (1Y) 3.8% 17.0% –
Gross profit CAGR (3Y) 0.2% 10.3% –
Operating income growth (1Y) 41.1% 134.9% –
Operating income CAGR (3Y) 9.5% 12.1% –
Net income growth (1Y) 52.8% 331.9% –
Net income CAGR (3Y) 3.6% 16.6% –
EPS growth (1Y) 52.0% 333.1% –
EPS CAGR (3Y) 3.9% 16.6% –
Operating cash flow growth (1Y) -35.9% -3.7% –
Operating cash flow CAGR (3Y) -6.2% -7.7% –
Free cash flow growth (1Y) -39.3% -4.1% –
Free cash flow CAGR (3Y) -7.4% -8.6% –

Profitability

14 metrics
MetricBMYABBVNVS
Gross margin 69.2% 73.7% –
EBITDA margin 28.2% 43.9% –
Operating margin 22.6% 32.2% –
Pretax margin 22.6% 19.4% –
Net margin 18.5% 15.7% –
FCF margin 18.6% 28.6% –
Operating cash flow margin 21.3% 30.4% –
Return on equity 40.4% – –
Return on assets 10.5% 7.3% –
Return on invested capital 14.0% 24.3% –
Return on capital employed 16.3% 21.6% –
Asset turnover 0.6x 0.5x –
Cash conversion (OCF / net income) 1.2x 1.9x –
Stock comp / revenue 1.1% 1.4% –

Financial Health

11 metrics
MetricBMYABBVNVS
Debt / assets 48.3% 54.8% –
Debt / equity 1.8x -17.7x –
Net debt / EBITDA 2.1x 2.4x –
Debt / FCF 4.6x 4.3x –
Liabilities / assets 73.6% 103.1% –
Equity / assets 26.4% -3.1% –
Interest coverage – – –
Current ratio 1.6x 0.9x –
Quick ratio 1.2x 0.6x –
Cash ratio 0.7x 0.2x –
Altman Z-score 2.66 2.78 –

Shareholder Returns

7 metrics
MetricBMYABBVNVS
Dividend yield 4.0% 2.3% 3.0%
Net buyback yield – 0.3% –
Shareholder yield 4.0% 2.6% 3.0%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusBMYABBVNVS
Forward P/E 9.4xFY2026 22.0xFY2026 17.1xFY2026
EPS, next fiscal year $6.74FY2026 $13.43FY2026 $9.38FY2026
EPS growth, next FY +9.6%FY2026 +34.3%FY2026 +4.5%FY2026
EPS growth, the year after -4.2% +24.3% +0.9%
Revenue, next fiscal year $52.37BFY2026 $69.64BFY2026 $53.97BFY2026
Revenue growth, next FY +8.7%FY2026 +13.9%FY2026 -1.0%FY2026
Revenue growth, the year after -9.3% -0.4% +19.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersBMYABBVNVS
Held by institutions 81.8% 74.9% 7.0%
Institutions holding 2,526 4,183 1,610
Change in shares held, QoQ +3.8% +2.6% -6.0%
Institutions buying 1,187 2,206 662
Institutions selling 991 1,507 562
Buyers to sellers 1.20 1.46 1.18

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

BMYABBVNVS
BMY 1.00 0.50 0.53
ABBV 0.50 1.00 0.52
NVS 0.53 0.52 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, BMY, ABBV and NVS?

AbbVie (ABBV) is the largest by market capitalisation: Bristol Myers Squibb (BMY) $129.31B, AbbVie (ABBV) $523.52B, Novartis Ag (NVS) $313.37B.

Which stock is cheaper, BMY, ABBV and NVS?

Bristol Myers Squibb (BMY) trades on the lowest price-to-earnings ratio (Bristol Myers Squibb (BMY) 14.0x, AbbVie (ABBV) 50.6x, Novartis Ag (NVS) 17.9x). On next year's consensus earnings, Bristol Myers Squibb (BMY) is cheapest (Bristol Myers Squibb (BMY) 9.4x, AbbVie (ABBV) 22.0x, Novartis Ag (NVS) 17.1x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

AbbVie (ABBV) grew revenue fastest over the trailing twelve months: Bristol Myers Squibb (BMY) +4.2%, AbbVie (ABBV) +10.7%.

Which company is more profitable?

Bristol Myers Squibb (BMY) has the highest net margin (Bristol Myers Squibb (BMY) 18.5%, AbbVie (ABBV) 15.7%). On return on invested capital, AbbVie (ABBV) leads (Bristol Myers Squibb (BMY) 14.0%, AbbVie (ABBV) 24.3%).

Which stock has performed better?

Over the past year Bristol Myers Squibb (BMY) returned the most: Bristol Myers Squibb (BMY) +30.4%, AbbVie (ABBV) +27.1%, Novartis Ag (NVS) +21.7%. Over five years, AbbVie (ABBV) compounded fastest (Bristol Myers Squibb (BMY) +1.3%/yr, AbbVie (ABBV) +20.3%/yr, Novartis Ag (NVS) +14.3%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, AbbVie (ABBV) has been the steadiest (Bristol Myers Squibb (BMY) 27.9%, AbbVie (ABBV) 25.3%, Novartis Ag (NVS) 27.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, BMY, ABBV and NVS?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, AbbVie (ABBV) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.